Agree 100% and there is a general agreement with the Wall Street analysts I work with that Rova-T will be a blockbuster. Their recommendation is ABBV strong buy recommendation. Thanks to Ricky G the share price will do well.
Interview With Rick G. CEO Abbvie Inc.
- Thread starter anonymous
- Start date
-
- Tags
- None
Stock breaking $64 and holding steady.UP UP and AWAY we GO. Gonzo wheeling and dealing Hes moving and shaking the wolfs of wall street !!!
75% of my 401k in ABBV, I will retire early now. go go go
I am so glad I stayed here and didn't jump ship like those idiots.
At times great companies have to dump load in order to maintain the target ROI - that's a fact of life !! Yes several were canned becuz they were incompetent and performed poorly. Our share price jumped afterwards...
My 401K is popping today Abbvie was a good hold in portfolio !!
FAKE REPLY....
everyone jumped onto a much better & faster ship...... including a captain & crew who have ultimate command and know how to steer through market challenges
as a newbie I am puzzled by the complaints about our CEO. I am so very happy working here and have already made good money. I have started paying off the college loans I accrewed over 6 years..
really dude..... keep on suckin that Haas/ricki koolaid
Keep up the good work, You'll be rewarded handsomely Good Luck
Some Highlights of Health Conference
Bill said that theres a lot of guessing going on right now about what changes the Trump administration will make. However, he noted that two specific potential changes could impact the company positively, the possible repeal and replacement of Obamacare shouldnt have a huge impact for AbbVie He also noted that around 80% of the companys dollar volume in the U.S. comes from non-government channels. Abbvie is very excited about the prospects for tax reforms and that AbbVie would love to see lower corporate tax rates, but the company isn't incorporating lower rates into any of its models yet
Bill said that theres a lot of guessing going on right now about what changes the Trump administration will make. However, he noted that two specific potential changes could impact the company positively, the possible repeal and replacement of Obamacare shouldnt have a huge impact for AbbVie He also noted that around 80% of the companys dollar volume in the U.S. comes from non-government channels. Abbvie is very excited about the prospects for tax reforms and that AbbVie would love to see lower corporate tax rates, but the company isn't incorporating lower rates into any of its models yet
Abbvie is very enthusiastic about the potential for tax reform that would allow the company to bring money parked overseas back into the U.S. at lower tax rates. Bill stated that this could be the best shot we have seen for meaningful tax reform in that area for a very long time.
Chase said , along with AbbVie's vice president of corporate strategy, Scott Brun, had a lot to say about the company's pipeline. Clinical studies of Venclexta in combination with other drugs in treating several types of cancer are promising. Rova-T is another cancer drug in AbbVie's pipeline with significant potential. Outside of oncology, the AbbVie executives highlighted autoimmune drug risankizumab. The company thinks that the candidate has tremendous potential in treating psoriasis. While risankizumab and other pipeline assets such as ABT-494 won't take Humira's place quickly, AbbVie believes that it will have a strong autoimmune franchise for a long time to come. The company also has high expectations for elagolix in treating endometriosis and uterine fibroids. Although AbbVie already markets Lupron for these indications, the drug has some adverse side effects. AbbVie is submitting elagolix for approval for treating endometriosis this year and expects to have data from a late-stage study targeting uterine fibroids in 2018. AbbVie has stated in the past that cancer drug Imbruvica will generate $5 billion in sales by 2020 and even more beyond then. The company still stands behind that prediction Maximizing currently approved indications should account for roughly 65% of Imbruvica's growth. Clinical studies are underway for the drug as a first-line treatment of mantle cell lymphoma (MCL) and as a combination first-line treatment for chronic lymphocytic leukemia (CLL). Chase said that AbbVie's strategy on this front is on track. Outside of oncology, the AbbVie executives highlighted autoimmune drug risankizumab. The company thinks that the candidate has tremendous potential in treating psoriasis. While risankizumab and other pipeline assets such as ABT-494 won't take Humira's place quickly, AbbVie believes that it will have a strong autoimmune franchise for a long time to come. Chase pointed to the ongoing battle with Amgen that AbbVie plans to assert its rights to 61 different patents to hold back Amgen from entering the U.S. market with its biosimilar to Humira. AbbVie has over 100 patents for the drug that cover multiple areas
And for all the Ricky haters Digest THIS .In 2012 Rick was retired,chilling, and relaxing.THEN MILES WHITE and Abbott board of directors who were the brainchild behind this spin to AbbVie approached Rick .....THEY gave Rick the golden goose They gave him Free Travel Free everything SO BLAME MILES WHITE. I understand that posting and venting and cutting up the "boss" makes you peons feel good ...WE understand and it's expected..... it's the nature of the beast and comes with the territory for us ....BUT at the end of the day, the rich get richer and the haters get $0 in thier pockets and mental satisfaction thats sustained for a short time until reality sets back in,,,,,, I'll take the $$$
Suggestion, Go the the fk)n Abbott board and bitc)h at MILES WHITE
Thanks
Suggestion, Go the the fk)n Abbott board and bitc)h at MILES WHITE
Thanks
If your "new captain,crew and fast ship" are so damn good and yall are on greener grass, Then WHY do you post Day and Night on our board ? It's easy to see disgruntled folks like you still mad after all these years .......2 Funni indeed !!! Sorry we couldn't keep you but apparently not as sorry as YOU are. Love that Viekira too
CASE CLOSED